SOURCE: Paragon Financial Limited

Paragon Financial Limited

January 18, 2012 08:20 ET

Major Pharmaceutical Firms Showing Appetite for Larger Acquisitions

The Paragon Report Provides Equity Research on Johnson & Johnson and Eli Lilly

NEW YORK, NY--(Marketwire - Jan 18, 2012) - According to a recent article from The Wall Street Journal, analysts are turning "bullish" on the pharmaceutical industry once again. There are 3,000 drugs in development in the U.S. today compared to about 2,000 a decade ago. Many of these medicines target unmet needs like Alzheimer's and stroke, where the advances in care can be substantial. Almost a third target forms of cancer, some of which are poorly treated today, the Journal reports. The Paragon Report examines the outlook for companies in the Drug Manufacturers - Major Industry and provides equity research on Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY). Access to the full company reports can be found at:

www.paragonreport.com/JNJ

www.paragonreport.com/LLY

2012 is expected to be a big year for M&A activity in the Pharmaceuticals industry. According to a recent article from FiercePharma drugmaker CEOs have been describing their appetites for deals in recent weeks. CEOs from large Pharmaceutical firms such as Pfizer, Roche, Sanofi and Bristol-Myers Squibb have expressed interest in deals for as much as $3B this year.

The Pharma Letter recently reported that while there were few multi-billion dollar deals last year, 2011 turned into a "bumper year" for the number of merger and acquisition deals for pharmaceutical, biotechnology and generic drugmakers with a total of 129 M&A announcements recorded.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Drug Manufacturers - Major Industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Regulation is expected to be a continual headwind for major pharmaceutical firms. A recent report from The New York Times reports that the Obama administration will soon require drug companies to disclose payments given to doctors. According to the article, around 25% of doctors receive cash from drug companies for consulting, speaking engagements, and more; in addition, almost two-thirds accept staff lunches or dinners out.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer